These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 10071987

  • 1. Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
    Lokshin A, Peng X, Campbell PG, Barsouk A, Levitt ML.
    Cancer Chemother Pharmacol; 1999; 43(4):341-7. PubMed ID: 10071987
    [Abstract] [Full Text] [Related]

  • 2. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
    Kalli KR, Bradley SV, Fuchshuber S, Conover CA.
    Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
    Lei W, Mayotte JE, Levitt ML.
    Anticancer Res; 1999 Sep; 19(1A):221-8. PubMed ID: 10226546
    [Abstract] [Full Text] [Related]

  • 4. EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells.
    Lei W, Mayotte JE, Levitt ML.
    Biochem Biophys Res Commun; 1998 Apr 28; 245(3):939-45. PubMed ID: 9588219
    [Abstract] [Full Text] [Related]

  • 5. Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.
    Lokshin A, Levitt ML.
    J Cell Biochem Suppl; 1996 Apr 28; 24():186-97. PubMed ID: 8806101
    [Abstract] [Full Text] [Related]

  • 6. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.
    Minniti CP, Maggi M, Helman LJ.
    Cancer Res; 1992 Apr 01; 52(7):1830-5. PubMed ID: 1312901
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
    Jänne PA, Taffaro ML, Salgia R, Johnson BE.
    Cancer Res; 2002 Sep 15; 62(18):5242-7. PubMed ID: 12234991
    [Abstract] [Full Text] [Related]

  • 8. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
    Kasayama S, Saito H, Kouhara H, Sumitani S, Sato B.
    J Cell Physiol; 1993 Feb 15; 154(2):254-61. PubMed ID: 7678839
    [Abstract] [Full Text] [Related]

  • 9. Suramin disrupts insulin-like growth factor-II (IGF-II) mediated autocrine growth in human SH-SY5Y neuroblastoma cells.
    Sullivan KA, Kim B, Buzdon M, Feldman EL.
    Brain Res; 1997 Jan 09; 744(2):199-206. PubMed ID: 9027379
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
    Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS.
    Lung Cancer; 2007 Apr 09; 56(1):25-33. PubMed ID: 17175059
    [Abstract] [Full Text] [Related]

  • 12. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
    Nakamura H, Takamori S, Fujii T, Ono M, Yamana H, Kuwano M, Shirouzu K.
    Cancer Lett; 2005 Dec 08; 230(1):33-46. PubMed ID: 16253759
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY.
    Clin Cancer Res; 2007 May 01; 13(9):2795-803. PubMed ID: 17473213
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
    Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K.
    Oncol Rep; 2004 Nov 01; 12(5):1053-7. PubMed ID: 15492792
    [Abstract] [Full Text] [Related]

  • 17. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 01; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo.
    Vincent TS, Hazen-Martin DJ, Garvin AJ.
    Cancer Lett; 1996 May 15; 103(1):49-56. PubMed ID: 8616808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.